Preliminary experiences with HOE 498, a novel long-acting converting enzyme inhibitor, in hypertensive patients.
The effect of various doses of the new angiotensin-converting enzyme inhibitor HOE 498 was compared with that of placebo in patients with mild essential hypertension. When a single dose of 2.5 mg of the drug was given, blood pressure was not significantly reduced despite a fall in converting enzyme levels. Single doses of 5 or 10 mg did reduce blood pressure, but complete inhibition of converting enzyme was apparent only with the 10-mg dose. Acute administration of a 20-mg dose proved to be unsuitable, since this was associated with too large a fall in pressure and the occurrence of symptomatic orthostatic hypotension. Although converting enzyme and blood pressure tended to recover in part 12 h after administration of the drug, both variables remained low even after 48 h.
P W
PW
de Leeuw
P L
PL
Lugtenburg
H
H
van Houten
J H
JH
Looman
W H
WH
Birkenhäger
D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors; D001794:Blood Pressure / Q000187:drug effects; D001643:Bridged Bicyclo Compounds / Q000627:therapeutic use*; D001952:Bridged-Ring Compounds / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D017257:Ramipril; D011897:Random Allocation; D013997:Time Factors
D000806:Angiotensin-Converting Enzyme Inhibitors; D001643:Bridged Bicyclo Compounds; D001952:Bridged-Ring Compounds; D017257:Ramipril